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Abstract
Background: The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is
growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use,
appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in
strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For
example, neuropathological investigations of Alzheimer’s disease pathogenesis can fall in disagreement with conclusions
reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research
methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field.
Purpose of review: Along with separate review articles covering fluid and imaging biomarkers in this issue of Alzheimer’s
Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases
course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease
research, commenting on appropriate use, interpretation, and considerations for implementation across different
neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other
disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel
modalities that have been proposed in the landscape of neurodegenerative disease research and care.
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Background
With 50 million individuals affected worldwide, neurode-
generative diseases remain without disease-modifying
treatments. Neuropathological investigations are critical for
closing intellectual gaps regarding pathophysiologic mech-
anisms, as postmortem examination serves as a gold
standard and provides adequate resolution to observe the
elements of pathophysiological cascades. However, they are
limited to cross-sectional assessment. The use of antemor-
tem biomarkers renders possible the detection of hallmarks
longitudinally, throughout disease stages. Even in situations
where conclusions drawn from antemortem biomarkers
might differ from postmortem observations, antemortem
biomarkers still offer utility. Here, we will illustrate ways
that evidence can be weighed to understand neurodegener-
ative diseases holistically, focusing on methodology and the
limitations and strengths of different modalities.
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Despite sometimes indirect associations with lesions,
neuropathologically validated biomarkers can be used to
assess disease course, particularly as degeneration relates to
clinical manifestations. For trials, biomarkers are of para-
mount importance. They are key for efficiently identifying
and tracking cohorts by defining inclusion criteria and out-
come variables [1]. As shown in a follow-up to an amyloid-
β (Aβ) immunization trial [2], neuropathology can be
informative for trials; however, the timelines associated with
postmortem donation hinder drug development. As treat-
ments emerge, biomarkers will become even more valuable
as diagnostic tools.
There are numerous biomarkers for neurodegenerative
diseases readily available or under development (Tables 1,
2, 3 and 4). In this issue of Alzheimer’s Research and Ther-
apy, separate articles will discuss fluid (Obrocki et al.) and
imaging (Young et al.) biomarkers for neurodegenerative
diseases. Priming this, it is important to consider how one
assesses the utility and biases of different modalities. We
will discuss ways that biomarkers are utilized in neurode-
generative disease research and care, commenting on ap-
propriate use, interpretation, and implementation. Finally,
we will consider where major knowledge gaps lie and how
novel biomarkers may fill them. This review will primarily
focus on Alzheimer’s disease, due to a significant deficit in
biomarkers useful for other neurodegenerative diseases;
however, we will comment on emerging techniques for
other diseases. Many of the themes discussed here on utility
can be readily applied across neurodegenerative diseases.
Disease fundamentals
Neurodegenerative diseases represent the confluence of a
range of pathophysiologic cascades with associated clinical
spectra. While typically defined by proteinopathic hall-
marks, it is unclear whether these hallmarks are driving the
disease or are themselves consequences of other underlying
processes. AD, frontotemporal lobar degeneration (FTLD),
and Parkinson’s disease are the most common neurodegen-
erative diseases. Overlapping diseases, otherwise known as
co-pathologies, are frequent and have complex contribu-
tions to clinical phenotypes [3].
Alzheimer’s disease
Alzheimer’s disease (AD) is the most common cause of de-
mentia with an incidence of 1700–2900/100,000 individuals
per year in the USA [4]. AD is a dual proteinopathy charac-
terized by the accumulation of tau neurofibrillary tangles
and extracellular Aβ plaques [5]. Postmortem studies indi-
cate that AD features a long preclinical phase where tau le-
sions and associated neuronal loss first appear in the
subcortical nuclei and begin to involve limbic regions with
associated subjective cognitive decline and neuropsychiatric
symptoms [1, 6–9]. Cortical tau lesions appear in later
stages [7], which correlate with the prototypical amnestic
Alzheimer’s clinical syndrome [1, 10]. Also in the preclin-
ical phase, Aβ lesions initially appear in the neocortical re-
gions followed by the allocortical, then subcortical, and
cerebellar involvement [11]. In contrast to tau lesions, the
distribution of Aβ is not significantly associated with symp-
toms [12]. Besides age, risk factors include cerebrovascular
diseases, diabetes, hypertension, obesity, dyslipidemia, and
genetic factors such as the APOE-ε4 allele and TREM2 mu-
tations [13, 14]. Approximately 5% of cases have an age of
onset under 65 and are referred to as early-onset AD cases.
Familial AD, accounting for about 20% of early-onset cases
and less than 1% of all AD cases, is mainly caused by rare,
dominantly inherited PSEN1, PSEN2, or APP mutations
(Table 5) [15–17].
Parkinson’s disease
Synucleinopathies are the second most common neurode-
generative disease [18]. The most common clinical pres-
entation of a synucleinopathy, Parkinson’s disease (PD),
has an estimated incidence of 10–18/100,000 individuals
Table 1 MRI biomarkers for neurodegenerative diseases
Biomarker Target Advantages Disadvantages
Volumetry (vMRI) Whole brain/medial temporal
lobe, hippocampus
Highly reproducible and sensitive
to disease-related changes
Late-stage biomarker; cannot provide information
on the cause of atrophy
Cortical thickness Cerebral cortex May improve classification between
dementia subtypes
Limited to neocortex; cannot be used to determine
the cause of atrophy
Functional MRI (fMRI) Regional/network functional
activity
Can evaluate robusticity of networks
at resting state and during tasks
Reproducibility and influence of vasculature
unclear
FLAIR/T2 imaging White matter lesions Highly sensitive Cannot determine the cause of the lesion
T2*/susceptibility-weighted
imaging
Microbleeds/myelin/iron Microbleed location can aid
diagnosis
Undesirable artifacts at air/tissue interfaces; few
longitudinal studies to date
Diffusion tensor imaging White matter Highly sensitive to white matter
damage
Fairly low resolution and sensitive to artifacts from
water diffusion; particularly sensitive to movements
Neuromelanin-sensitive Locus coeruleus, substantia
nigra
Sensitive to noradrenergic and
dopaminergic subcortical nuclei
Semi-quantitative assessment/not disease specific
Abbreviations: MRI magnetic resonance imaging, FLAIR fluid-attenuated inversion recovery
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per year in the USA [19]. Synucleinopathies feature the
aggregation of α-synuclein in the form of Lewy bodies
starting subcortically, spreading into limbic and neocor-
tical regions [20]. Generally, synucleinopathies present as
PD, PD dementia, or dementia with Lewy bodies, which
collectively feature varying degrees of behavioral, cogni-
tive, and autonomous symptoms on top of motor dysfunc-
tion. Mutations in a number of genes (Table 5) have been
linked to synucleinopathies [10, 21], as has pesticide ex-
posure and traumatic brain injury [22].
Frontotemporal lobar degeneration
FTLD is nearly as prevalent as early-onset AD in demen-
tia cases below the age of 65 with an incidence of 1.6–
4.1/100,000 individuals annually in the USA and Europe
[23, 24]. FTLD describes a spectrum of diseases
Table 2 PET biomarkers for neurodegenerative diseases
Biomarker Target Advantages Disadvantages
18F-FDG Glucose
metabolism
Capable of detecting dysfunction that has not necessarily
involved atrophy; well-validated for clinical research
Variability in methods of analysis between
studies/centers
18F-FDDNP AD lesions 18F half-life does not require on-site cyclotron Does not differentiate Aβ or tau aggregations
11C-PBB3 Tau lesions Sensitive to both AD-type tau aggregations and non-AD
tau aggregations; correlates with clinical progression
Short half-life of 11C; relatively low affinity




Tau lesions High affinity to aggregated tau; distribution of binding
reflects clinical presentations; 18F half-life does not require
on-site cyclotron
Off-target binding to neuromelanin and choroid
plexus; poor reliability in early NFT stages; preferential
binding to mixed 3R/4R tau rather than isolated
3R or 4R tau
18F-GTP1 Tau lesions Ligand binding maps to known distribution of AD-tau
aggregations; 18F half-life does not require on-site cyclotron
Yet to be fully validated; possible high non-specific
binding in basal ganglia
18F-MK6240 Tau lesions Extremely high binding affinity to tau aggregations; good
brain delivery and washout; 18F half-life does not require
on-site cyclotron
Likely preferential binding to mixed 3R/4R tau rather
than isolated 3R or 4R tau; off-target binding to
neuromelanin
18F-RO6958948 Tau lesions High binding affinity to tau aggregations; preliminary
study shows longitudinal increases in AD; 18F half-life
does not require on-site cyclotron
Yet to be fully validated; no significant binding in
3R or 4R tauopathies
18F-THK5351 Tau lesions High binding affinity to tau over Aβ aggregations; 18F
half-life does not require on-site cyclotron
High non-specific retention in the subcortical white
matter; high MOA-B binding
18F-THK5105 Tau lesions High binding affinity to tau over Aβ aggregations; 18F
half-life does not require on-site cyclotron
High non-specific retention in the subcortical white
matter; inferior signal-to-background ratio
18F-THK523 Tau lesions High binding affinity to tau over Aβ aggregations; 18F
half-life does not require on-site cyclotron
High non-specific retention in the subcortical white
matter; poor in vivo visualization of tau deposition
18F-PI2620 Tau lesions Binds to both 3R/4R mix tau and 3R tau (Pick’s disease);
high binding affinity to tau over Aβ aggregations and
MOA-A/MOA-B; 18F half-life does not require on-site
cyclotron
Yet to be fully validated
18F-PM-PBB3 Tau lesions Indication that ligand is sensitive to both AD and
non-AD tauopathies; little binding to MOA-A and
MOA-B; 18F half-life does not require on-site cyclotron




High affinity to fibrillar Aβ; best studied of available
Aβ PET tracers




High affinity to fibrillar Aβ; 18F half-life does not require
on-site cyclotron





High affinity to fibrillar Aβ; 18F half-life does not require
on-site cyclotron





High affinity to fibrillar Aβ; 18F half-life does not require
on-site cyclotron
Not specific to AD amyloidosis
18F-NAV4694 Amyloid-β
aggregations
Excellent agreement with 11C-PiB; 18F half-life does not
require on-site cyclotron
Not specific to AD amyloidosis
11C-UCB-J Synapses
(SV2A)
High affinity to protein expressed on synapses Short half-life of 11C; relatively new tracer and not
well-validated in dementia populations
Abbreviations: PET positron emission tomography, FTD frontotemporal dementia, MOA-B monoamine oxidase B, PiB Pittsburg Compound-B, CAA cerebral amyloid
angiopathy, FDG fluorodeoxyglucose, SV2A synaptic vesicle glycoprotein 2A
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characterized by vacuolation, gliosis, and neuronal loss
in the external cortical layers of predominantly frontal
and temporal neocortices and features the accumulation
of tau, TDP-43, or fused-in sarcoma, which define the
FTLD subtype [25, 26]. FTLD is associated with a
spectrum of frontotemporal dementia (FTD) syndromes
ranging from behavioral, language, to motor variants.
Amyotrophic lateral sclerosis (ALS) and other motor
neuron diseases can be considered part of the FTLD
spectrum due to common neuropathologic and genetic
features [27]. Roughly one third of all FTD cases are fa-
milial [28].
Huntington’s disease
Huntington’s disease (HD) is a rare, autosomal dominant
disease with an incidence of 0.16–0.94/100,000 individ-
uals annually [29]. The age of onset of symptoms is
typically in the mid-40s but can range from as young as
2 to over 80 and features chorea with behavioral and
cognitive symptoms [30]. While there is a correlation
between CAG repeat length and age of onset [31, 32],
there is a high degree of variability making the predictive
power of CAG repeat size poor, illustrating the
complexity involved with treating HD. HD features pro-
gressive neuronal loss and astrogliosis in the striatum
[33] as well as significant degeneration of the cortical re-
gions, cerebellum, and brainstem nuclei [34]. While the
huntingtin polyglutamate expansion leads to protein ag-
gregation and transcriptional dysregulation, the mecha-
nisms tying this to neuron loss are unclear.
Prion diseases
Prion diseases are characterized by spongiform enceph-
alopathy with underlying neuronal loss, gliosis, and ag-
gregation of the prion protein (PrP) encoded by the
PRNP gene [35]. PrP distinguishes prion diseases from
other neurodegenerative diseases that may feature prion-
like mechanisms, whereby misfolded amyloidogenic pro-
teins spread throughout the brain via seeding aggrega-
tion processes. Several genetic, sporadic, and acquired/
zoonotic forms of prion diseases exist with sporadic
Creutzfeldt-Jakob disease (sCJD), accounting for roughly
85% of cases [36]. With a mortality rate of 1.5–2 individ-
uals per million, sCJD is an extremely rare disease with
an incidence rate that is difficult to ascertain [36]. Rele-
vant clinical features include rapid cognitive decline,
Table 3 CSF biomarkers for neurodegenerative diseases
Biomarker Target Advantages Disadvantages
Aβ42 Amyloid-β peptides Strong correlation with 11C-PiB PET status Different cutoff values used in different labs
Aβ40 Amyloid-β peptides Added value when combined with Aβ42 Not a clinically meaningful biomarker in isolation
Aβ42/Aβ40 ratio Amyloid-β peptides Stronger diagnostic and prognostic value
than Aβ42 alone
Not yet widely implemented
Aβ42/Aβ38 ratio Amyloid-β peptides Stronger diagnostic and prognostic value
than Aβ42 alone
Not yet widely implemented
t-Tau Tau peptides Reasonably sensitive for late-stage AD Poor specificity, not clinically useful in isolation
p-Thr181 tau Tau peptides Reasonably sensitive for late-stage AD Poor specificity, not clinically useful in isolation
NfL White matter damage Indicates the presence of neurodegeneration Increased in multiple neurodegenerative diseases
Abbreviations: Aβ amyloid-β, NfL neurofilament light chain
Table 4 Blood biomarkers for neurodegenerative diseases
Biomarker Target Advantages Disadvantages
Aβ42/Aβ40
ratio
Amyloid-β peptides Automated platform available for
measurements
Difference in values between disease groups too small
to be used as a diagnostic tool. Levels can be affected
by pattern change from monomer to protofibrils in blood.
MDS-OAβ Amyloid-β oligomers Differentiates AD patients from HC with high
sensitivity and specificity, not affected by
pattern change in the blood
Poorly validated and limited availability of technology
relative to ELISA-based methods
IIR assay Amyloid α-helix versus
β-sheet form
Detects biophysical properties of pathologic
forms of amyloid instead of just concentrations
Poorly validated and limited availability of technology
relative to ELISA-based methods
p-Thr181 tau Tau peptides Can accurately predict 11C-PiB PET status Does not differentiate between tauopathies other than
AD
t-Tau Tau peptides Automated platform available for
measurements
Large overlap between diagnostic groups
NfL White matter damage Indicates the presence of neurodegeneration;
strong correlation with CSF NfL
Increased in multiple neurodegenerative diseases
Abbreviations: MDS-OAβ Multimer Detection System-Oligomeric Amyloid β, IIR assay immune-infrared sensor assay, NfL neurofilament light chain
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myoclonus, akinetic mutism, visual and cerebellar difficul-
ties, and pyramidal or extrapyramidal features. A definitive
identification requires neuropathological confirmation with
postmortem or biopsied tissue. Probable identification re-
quires either an electroencephalogram, magnetic resonance
imaging (MRI), or cerebrospinal fluid (CSF)-based bio-
markers with the use of real-time quaking-induced conver-
sion (RT-QuIC) preferred over 14-3-3 detection [37].
In vivo biomarkers for the study of
pathophysiology and etiology
Decades of neuropathological studies augmented by novel
biomedical tools have revealed that many complex, interre-
lated mechanisms underlie neurodegenerative diseases. A
principle limitation of the cross-sectional nature of neuro-
pathology is difficulty in assessing temporal relationships.
Neuropathological investigations typically only observe
end-stages; however, existing population-based cohorts can
capture the full range of disease progression [38]. Detecting
and addressing early phases of pathophysiological cascades
are likely key for successful therapeutics; thus, a granular
understanding of the early underlying biology and the iden-
tification of biomarkers representing these changes is
paramount.
Given the clear etiology and sometimes predictable age
of onset, several studies have focused on hereditary neuro-
degenerative diseases to investigate early disease stages. For
example, positron emission tomography (PET) imaging
studies of familial AD cases have suggested that brain Aβ
deposition begins up to 20 years before clinical symptoms,
while cortical tau deposition arises roughly 6 years before
onset [39, 40]. Similarly, biomarker studies of FTLD muta-
tion carriers suggest that pathological changes start de-
cades before symptoms [41]. These studies demonstrate
that a latency period exists prior to clinical decline which
should be targeted therapeutically, confirming neuropatho-
logical observations. There is evidence that plasma Aβ42/
40 is sensitive to preclinical amyloidosis, providing a more
economical means than CSF or PET to identify partici-
pants in trials focused on early stages [42].
Curiously, conclusions from in vivo studies of the relative
onset of Aβ and tau lesions in AD often conflict with inves-
tigations using large postmortem case series that indicate
that tau lesions occur prior to Aβ deposition in the brain
[6, 7]. This may be due to biases in the design of event-
based modeling approaches with biomarkers. Young and
colleagues [43] found that CSF levels of total tau and phos-
phorylated tau become abnormal prior to CSF levels of
Aβ42, concurring with postmortem studies. It was not until
they isolated the cohort to those who were already Aβ+,
APOE+, or Aβ+ and APOE+, applying data-driven
autopsy-validated cutoffs, which the sequence of biomarker
changes recapitulated those typically found in biomarker
studies. Further, differences between investigators regarding
thresholds and characterization of what belongs to “clinic-
ally meaningful” disease spectra will affect the conclusions
drawn. To illustrate, Weigand and colleagues found that
Aβ PET-negative and tau PET-positive individuals tend to
Table 5 Genetic biomarkers for neurodegenerative diseases
Gene Protein Associated Syndrome(s) Reference
APP Amyloid precursor protein EOAD (familial), CAA Tanzi et al., 1987 [15]
PSEN1 Presenilin 1 EOAD (familial) Sherrington et al., 1995 [16]
PSEN2 Presenilin 2 EOAD (familial) Levy-Lahad et al., 1995 [17]
MAPT MAPT bvFTD, PSP Hutton et al., 1998 [18]; Poorkaj et al., 1998 [19]
C9orf72 C9orf72 bvFTD, ALS Renton et al., 2011 [20]
GRN Progranulin bvFTD, CBS Gass et al., 2006 [21]
VCP Valosin-containing protein ALS Johnson et al., 2010 [22]
TARDBP TDP-43 ALS Shreedharan et al., 2008 [23]
SOD1 Superoxide dismutase 1 ALS Rosen et al., 1993 [24]
FUS Fused-in sarcoma ALS Kwiatkowski et al., 2009 [25]; Vance et al., 2009 [26]
HTT Huntingtin HD HDCRG, 1993 [27]
SNCA α-synuclein PD, DLB, MSA Kruger et al., 1998 [28]
GBA β-glucocerebrosidase PD, DLB, Gaucher Sidransky and Lopez, 2012 [29]
PRNP Prion protein Prion Liao et al., 1986 [30]; Kretzschmar et al., 1986 [31]; Hsiao et al., 1989 [32]
ApoE (ε4 allele) Apolioporotein-E AD (risk factor) Corder et al., 1993 [33]; Saunders et al., 1993 [34]
TREM2 TREM2 AD (risk factor) Guerreiro et al., 2013 [35]; Jonsson and Stafansson, 2013 [36]
Abbreviations: EOAD, Early-onset Alzheimer’s disease; MAPT, Microtubule associated protein tau; CAA, Cerebral amyloid angiopathy; bvFTD, Behavioral-variant
frontotemporal dementia; PSP, progressive supranuclear palsy; ALS, Amyotrophic Lateral Sclerosis; TDP-43, Transactive response DNA binding protein 43 kDa; FUS, Fused-
in Sarcoma; CBS, corticobasal syndrome; HD, Huntington’s disease; PD, Parkinson’s disease; DLB, Dementia with Lewy bodies; MSA, multiple system atrophy; AD,
Alzheimer’s disease; TREM2, Triggering receptor expressed on myeloid cells 2
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present with subtle cognitive changes, which they interpret
to represent early AD-related changes [44]. That is to say
that tau PET-positive and Aβ PET-negative individuals be-
long to an early phase of the disease spectra. This argument
is strengthened by evidence that tau PET distribution pre-
dicts subsequent atrophy, whereas Aβ PET does not [45].
At the same time, others would characterize tau PET-
positive and Aβ PET-negative individuals as having “sus-
pected non-Alzheimer disease pathophysiology,” implying
that they belong to a different disease spectrum instead of
a, rather, early phase of AD that may later feature both le-
sions [1]. As the field remains split regarding the precise,
biological definition of AD stages, interdisciplinary efforts
must harmonize observations by acknowledging their var-
ied, but complementary, strengths and limitations.
Information gleaned from longitudinal studies has been
used to construct models of multiple biomarkers. The
widely recognized “Jack curves” [46], for example, were
explicitly intended to provide a “model of [AD] bio-
markers” to help stage cases in vivo [46], setting a prece-
dent for the 2018 guidelines for an in vivo research
definition of AD [3]. However, the curves should not be
interpreted as providing a comprehensive model of AD
pathophysiology and are subject to revision as biomarkers
become more advanced [46].
Challenges in interpreting pathobiology
When combining biomarkers in a study, it is also import-
ant to account for differences in how they represent re-
spective disease hallmarks. Importantly, the biomarkers
must have a comparable target engagement with their
respective hallmarks or, at the least, empirical measures of
target engagement to adjust for different sensitivities. For
fluid biomarkers, the kinetics of how biomarkers appear in
the fluid samples (i.e., how a protein might be digested,
processed, or passed into the CSF or blood) may differ
and must be accounted for. While expensive and labor-
intensive, kinetics can be measured through in vivo label-
ing techniques [47] that track protein production and
clearance. Significant technological gaps exist with the de-
tection of soluble biomarkers in vivo. Of note, lipid perox-
idation and metabolism have been implicated in
neurodegenerative diseases [48], yet current tools limit the
degree to which this can be monitored in vivo. Similarly,
robust fluid biomarkers of blood-brain barrier function
have been lacking, with several under development.
Idiosyncratic properties of pathophysiological processes
can manifest misleading results in biomarker-based stud-
ies of pathophysiology. For PET, there is a heterogeneous
uptake of different ligands throughout the brain, and dif-
ferences in this uptake, off-target binding, and imaging
sensitivity should be accounted for. In AD, early tau le-
sions begin in the brainstem nuclei followed by limbic in-
volvement, whereas Aβ lesions begin in the neocortical
regions [7, 8, 49]. Several limitations with PET may lead to
biases in detecting these two patterns. PET cameras are
susceptible to partial volume effects and lack resolution to
measure tau ligand binding in the subcortical regions,
which are small but can have profound neurobiological
and behavioral effects [6, 8, 9, 50–54]. Lowe and col-
leagues demonstrated that tau PET positivity denotes indi-
viduals who, at autopsy, are all already at Braak stage IV
[55], at which point many subcortical structures and lim-
bic regions would already feature significant degeneration
[8, 9, 51]. Further, a tau PET imaging study [56], with rela-
tively low SUVR values for positivity, estimated the preva-
lence of Braak stage 0 individuals as roughly 55% of their
study population (n = 161) while a population-based aut-
opsy study [6] featured just 28% of the study population
(n = 455) as Braak stage 0. Depending on the thresholds
used, tau PET recapitulates the histological progression of
tau lesions seen at autopsy; however, the thresholds set
may render the tau PET “Braak stage” an underestimate
of the true Braak stage at autopsy, particularly at early
stages, as seen in these studies [56, 57]. Additionally, some
of the first regions to feature protein aggregation in neuro-
degenerative diseases contain neuromelanin, which many
PET ligands will non-specifically bind to [58, 59]. By con-
trast, the signal from 11C-PiB and other ligands targeting
Aβ can detect early, neocortical involvement of plaques
[60], making Aβ easier to detect.
Other biological factors, including the significant im-
pact of low-abundance hallmarks such as mutant hun-
tingtin, synaptic proteins, and neurogranin should also
be considered, as their low abundance may lead to
underestimation of the roles these hallmarks play using
event-based modeling approaches. To illustrate, differ-
ences in relative abundances of tau versus Aβ lesions,
due to tau tangles accumulating within cells and Aβ oc-
curring extracellularly, make the relative determination
of proteinopathy onset difficult in vivo. The strengths of
Aβ biomarkers may outweigh the weaknesses of tau bio-
markers, potentially overrepresenting the relative in-
volvement of Aβ versus tau lesions at different AD
stages, especially in early stages. The development of
biomarkers and studies with multidisciplinary, postmor-
tem observations are needed to reconcile these issues.
Biomarkers are invaluable for elucidating pathophysiology
with appropriate caution. Specific biological questions may
call for different implementations of biomarkers, and estab-
lishing universal guidelines for their research use would be
presumptuous. Biomarker status may be sensitive and spe-
cific to certain neuropathological diagnoses; however, one
should not assume that clinical utility implies broad-
sweeping research utility or vice versa. In vivo, labeling ap-
proaches and high-resolution biomarker-neuropathology
correlations are critical for assessing the validity of individ-
ual biomarkers as they relate to underlying lesions [47].
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Unless the extent of the factors connecting lesions to the
detection of their corresponding biomarkers is elaborated,
one must be cautious when employing biomarkers in stud-
ies of disease etiology, particularly when comparing bio-
markers with varied biases.
Biomarkers for the study of disease intervention
Rigorous validations of biomarkers through methods
such as kinetics quantification [47] or postmortem cor-
relation are necessary considerations for the selection of
inclusion criteria and outcomes for clinical trials. Those
trials that target underlying proteinopathy, such as the
Aβ-modifying drugs for the treatment of AD, require an
in vivo measurement of lesions to verify target engage-
ment. By contrast, intervention studies that focus on
specific symptoms of diseases, such as depression, may
not require in vivo measurements of proteinopathy.
Nevertheless, an operational, validated biomarker-based
definition of different diseases is paramount for trials fo-
cused on disease-modifying therapies.
The 2018 NIA-AA guidelines for an in vivo research
definition of AD set an outline for clinical trials based
on a biomarker definition of AD [1]. The authors argue
that since Aβ and tau lesions, together with neurodegen-
eration, define AD postmortem, participants should be
identified in vivo based on these hallmarks. There re-
mains disagreement regarding which biomarkers can be
used to identify these hallmarks, though. Biomarkers for
FTLD, synucleinopathies, and other neurodegenerative
diseases are underdeveloped or have not yet been fully
validated so a similar biomarker definition of other neu-
rodegenerative diseases has yet to be established.
Aβ and tau PET imaging could serve as useful out-
comes in clinical trials due to their ability to detect re-
gional changes in vivo preceding significant atrophy [61,
62]. The implementation of tau PET in tau-targeting
therapies is particularly encouraged due to the target’s
associations with neurodegeneration and cognition [45,
63]. Further consideration regarding proteinopathy bio-
marker implementation in AD trials is warranted,
though, as therapeutic changes in Aβ load have not asso-
ciated with clinical changes or neurodegeneration [2].
Fluid levels of neurofilament light chain (NfL) are candi-
date outcomes for trials as they correlate with cognitive
status and atrophy; however, they are not specific to
underlying proteinopathy and instead represent the pres-
ence of general neurodegeneration [64].
Similarly, therapeutic development for HD serves to bene-
fit from biomarker development. Despite the existence of a
highly specific and sensitive genetic marker [62, 65], it is dif-
ficult to predict the age of onset [30]. Furthermore, clinical
trials cannot rely on genetic markers as they will not change
following a therapeutic intervention. Decreased striatal up-
take of phosphodiesterase-10 PET tracer [66], atrophy in
MRI [67], and plasma levels of IL-8, TNF-α [68], and NfL
may be valuable markers for HD progression that could be
used for evaluating the effectiveness of interventions.
Novel ultrasensitive immunoassays make blood bio-
markers promising for the future as less invasive, cost-
effective screening instruments [69]. In AD, plasma Aβ42
is decreased compared to controls [70, 71], and plasma
Aβ42/40 is reduced in Aβ PET-positive individuals [72,
73]. Plasma NfL, which correlates with CSF NfL, may be
useful for tracking neurodegeneration and associates with
cognitive decline and atrophy [64, 74]. These require fur-
ther validation but may serve as more accessible markers
in the future [75]. Factors such as how plasma Aβ levels
change in response to disease-modifying therapies, expos-
ure time to drugs, and harmonization of analytical method-
ology remain a challenge [75, 76]. With well-characterized
cohorts that now include Aβ PET and CSF measures, the
opportunity to use an “endophenotype” approach to dis-
cover peripheral markers of lesions is increasing. Pilot data
from discovery mass spectrometry and large panel-based
approaches suggest associations of many plasma proteins
and metabolites with AD [65, 77, 78]. However, these data
should be interpreted with caution, as they are derived
from multimarker panels with the mechanistic understand-
ing of the associations lacking.
Developing biomarkers for clinical use
In individuals with suspected neurodegenerative diseases
that lack known monogenic etiologies, biomarkers are
currently used on an exclusionary basis to rule out other
diseases and may be used to support a specific diagnosis
of a neurodegenerative disease. Other biomarkers are in
the pipeline for clinical validation and determination of
clinical value.
For example, structural MRI can be used to exclude
space-occupying lesions and assess patterns of atrophy
that aids diagnoses made by neurological assessment.
Functional MRI and 18F-FDG PET can also be used to
identify the affected brain regions and networks [10, 79,
80]. NfL is the best-established fluid marker for measur-
ing neurodegeneration but has poor specificity [81]. A
summary of currently available biomarkers that may
hold clinical promise is provided in Tables 1, 2, 3 and 4.
Following the discovery and validation phases of bio-
marker development, standardization and clinical utility
are key steps for clinical implementation. In these phases
of biomarker development, key questions regarding opti-
mal procedures, reproducibility, and elucidation of the bio-
logical relevance can be assessed. Further, these phases will
determine the sensitivity and specificity of each biomarker
to a given disease. For example, plasma NfL well represents
the underlying neurodegeneration [74], but the consistency
between labs is unclear and a great deal of overlap between
diagnostic groups exists [81]. Another consideration in the
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standardization phase is the establishment of cutoffs for
diagnostic thresholds. This requires a large study to assess
biomarker values across diverse healthy and disease popu-
lations, accounting for possible differences in sample col-
lection and analysis.
A further criterion for establishing biomarkers in clin-
ical practice, even when biologically meaningful, is the
utility for patient management which can determine fi-
nancial coverage for the test. An ongoing study in the
USA is examining how Aβ PET results influence patient
management [82]. Preliminary results suggest that man-
agement is influenced by the use of Aβ PET; however,
the effects on the prognosis are not yet known [82].
New frontiers in biomarkers
In addition to the array of targets that can be detected by
standard fluid and imaging biomarkers, other features of
neurodegenerative diseases have been proposed as viable
biomarkers of disease progression. One technique, the
Multimer Detection System-Oligomeric Aβ, examines the
tendency of plasma proteins to oligomerize, circumvent-
ing issues in measuring concentrations of Aβ itself [83].
Another uses biophysical properties associated with the
propensity of the amyloid protein to form β-sheets to
measure blood levels with an immune-infrared sensor
assay [84, 85]. In vivo measurement of an early-affected
region, the locus coeruleus, is being explored as a viable
early biomarker using specialized MRI sequences and ana-
lysis [52]. In line with this, pupillometry is being explored
as a measure of noradrenergic activity and, thus, locus
coeruleus integrity [52]. Signal analysis from transcranial
magnetic stimulation, electroencephalography, or magne-
toencephalography has also shown promise as a bio-
marker of functional connectivity and may be sensitive to
early changes [86–88]. Other functional readouts, such as
sleep polysomnography and app-based digital phenotyping
assessments have been proposed as early biomarkers as
well [89–91].
Conclusions
In combination with basic science and neuropathologic
examination, biomarkers are invaluable for building a
narrative on pathophysiology, clinical etiology, and strat-
egies for interventions. As there are numerous ways bio-
markers may be informative, caution must be exercised
to ensure appropriate interpretation given the varied
limitations of different modalities. Importantly, a signifi-
cant gap remains for biomarker availability in non-AD
neurodegenerative diseases. As the field works towards
therapies for dementias, there continues to be a grave
need for novel biomarkers, improved development of
existing tools, standardization, and improved accessibil-
ity for clinical and research communities.
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